A prognostication tool for early classic Hodgkin's lymphoma (cHL) outperformed a widely used classification system in ...

Although regular monitoring in the first hours of stroke onset is vital to a patient’s recovery, ... and the Medical Research Future Fund (ID F02176) in Australia; and from Genentech, Inc. in the ...

Genentech is letting go of 143 employees who are based out of the company's headquarters in South San Francisco. The workforce reduction will be complete by July 14, according to a California ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, an i ...

SOUTH SAN FRANCISCO, Calif., June 02, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq® (atezoliz ...

Genentech’s first CMO on why ‘elite’ marketing has never been more important in healthcare With a background in biochemistry, Erica Taylor admits her route into marketing is not common, but it has ...

According to Genentech, the partnership will help to transform its GenAI models and algorithms into a “next-generation AI platform” operating at the interface between biology and computation.

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced its decision to advance prasinezumab—a potential anti-alpha-synuclein antibody—into Phase III clinical development for ...

SOUTH SAN FRANCISCO, Calif., May 31, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall survival (OS) analysis of ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein ...